A Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer

17178ETCTN-10716-NCT07147231OpenA Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer10716NCT07147231NationalAdultTreatmentIINationalOtherWeinberg, BenjaminGeorgetown University Medical Center : Isabel Frye; Lombardi Comprehensive Cancer Center : Isabel FryeGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC)17359Isabel FryeIsabel Fryeif151@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>